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In vivo efficacy and tolerability of this inert organo-osmium anticancer complex is dependent on the 
time of administration (day versus night), consistent with preferential activation at specific stages of 
the circadian cycle. 
 
ABSTRACT  
The organo-osmium complex [OsII(ɳ6-p-cym)(PhAzPy-NMe2)I]+ (FY26) exhibits promising in vitro 
antitumour activity against mouse hepatocarcinoma Hepa1-6 and other mouse or human cancer cell 
lines. Here, we drastically enhance water solubility of FY26 through the replacement of the PF6-
counter-anion with chloride using a novel synthesis method. FY26.PF6 and FY26.Cl displayed similar 
in vitro cytoxicity in two cancer cell models. We then show the moderate and late anticancer efficacy 
of FY26.PF6 and FY26.Cl in a subcutaneous murine hepatocarcinoma mouse model. Both efficacy and 
tolerability varied according to FY26 circadian dosing time in hepatocarcinoma  tumour-bearing 
mice. Tumour and liver uptake of the drug were determined over 48 h following FY26.Cl 
administration at Zeitgeber 6 (ZT6), when the drug is least toxic (in the middle of the light span when 
mice are resting). Our studies suggest the need to administer protracted low doses of FY26 at ZT6 in 
ZT06 ZT18
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order to optimize its delivery schedule, for example through the use of chrono-releasing 
nanoparticles.  
 
SIGNIFICANCE TO METALLOMICS STATEMENT 
Metallodrugs differ from most organic drugs in that they are prodrugs, which undergo 
transformation by ligand substitution and redox reactions before reaching target sites. Here we 
study the in vitro and in vivo efficacy of an organo-osmium anticancer complex FY26 – a relatively 
inert complex activated in cancer cells by attack on its azo-bond by the tripeptide glutathione. We 
find that the efficacy and tolerability of FY26.PF6 or FY26.Cl are dependent on the time of 
administration, consistent with a role for the circadian clock in controlling expression of genes 





































There is a need for anticancer drugs with new mechanisms of action to complement platinum drugs 
in the clinic, reduce side-effects and overcome emerging platinum resistance. Complexes of 
ruthenium have been investigated in  clinical trials,1, 2 and compounds of heavier congener osmium 
are being explored.3, 4 Although in the same periodic group, and often possessing complexes of 
similar composition (oxidation state, ligand set, size and geometry), the reactivity of ruthenium and 
osmium complexes can differ markedly. Notably, organo-Os(II) arene complexes hydrolyse much 
more slowly and bound water ligands are more acidic.5  
 
Numerous experimental and clinical studies have highlighted the relevance of circadian timing in 
drug administration for the optimisation of pharmacological effects.6, 7 For instance, dosing an 
anticancer medication at a specific time with reference to circadian rhythms can increase or 
decrease both efficacy and tolerability.8-10 As demonstrated for 28 anticancer agents belonging to 
various classes, the administration of a drug at the circadian time when it is best tolerated often 
achieves best antitumour activity.6, 7, 9, 10 Here we sought the relevance of this 
chronopharmacological principle along preclinical developmental stages of organo-Os complexes.  
 
Organometallic half-sandwich Os(II) arene complexes with phenylazopyridine (PhAzPy) bidentate 
ligands show promising anticancer activity in vitro against a variety of cancer cell lines,11, 12 and also 
in vivo.13 In contrast to less-active organo-Os(II) drugs with N,N-chelated diamine or N,O-chelated 
picolinate ligands, which rely primarily on the dissociation of labile ligands followed by DNA binding. 
14, 15 Iodido Os(II) PhAzPy complexes are considerably more stable in aqueous media and exhibit a 
mechanism of activity involving intracellular ROS production. These inert complexes are activated in 
cancer cells by attack of glutathione on the azo bond of the chelated PhAzPy ligand.16, 17 A key 
complex, FY26.PF6 ([OsII(ɳ6-p-cym)(PhAzPy-NMe2)I]PF6), is on average 49 times more active than 




































growth of HCT-116 human colon cancer xenografts in mice.13 Furthermore, it is up to 64 times more 
selective towards A2780 ovarian cancer cells over MRC5 fibroblasts when applied synergistically 
with L-buthionine-sulfoximine.19 The structure of FY26 and its biomolecular mechanism of action are 
shown in Figure 1. 
 
In vitro experiments have also demonstrated time-dependent efficacy of FY26.PF6 against both 
mouse Hepa1-6 hepatocarcinoma and human HCT116 colon carcinoma in cell cultures in Figure 
1A.20 More specifically, the IC50 of FY26.PF6 varied by 40% according to the timing of in vitro drug 
exposure of cultured Hepa1-6 cells, following the synchronization of their circadian clocks with a 24-
h periodic temperature cycle.20, 21 The least toxic timing for FY26.PF6 administration was near the 
minimum of the sinusoidal temperature cycle which synchronizes the genetic circadian clocks of the 
cells in the Petri dishes over the 24 hours. FY26.PF6 chronopharmacology mechanisms depend upon 
clock gene Bmal1 proficiency, and involve circadian dependent FY26 uptake and possibly efflux2. 
Moreover, the toxicity of FY26.PF6 also varies according to dosing time in mice.21 The best tolerated 
time for FY26 in mice following dosing is near the middle of the light span, which corresponds to the 
low point in their endogenous circadian rhythm in core body temperature. Strikingly, the circadian 
rhythm in FY26.PF6 toxicity for Hepa1-6 cells and for mice differs from those in oxaliplatin toxicity by 
several hours, hence further highlighting the pharmacological differences between these organo-
osmium complexes and platinum metallodrugs on the temporal timescale.21 
Here we aimed to optimize the chemical solubility of FY26 prior to the determination of FY26 
efficacy and tolerability in Hepa1-6 tumour-bearing mice. We further obtained insight in to its tissue 








































FY26 synthesis and characterisation 
FY26.PF6 was synthesised and characterised as previously reported,12 however, it was poorly water 
soluble. We previously reported that the anion (X) has a major effect on aqueous solubility for 
organo-osmium complexes.22 Here we synthesised FY26 as a chloride salt (FY26.Cl) instead of PF6. 
Furthermore, the route by which FY26 is synthesised was improved upon, now involving a 2-step 
one pot synthesis from [Os(η6-p-cym)Cl2]2. FY26 was firstly isolated as an iodide salt (FY26.I), which is 
an important purification step prior to anion exchange with chloride. The anion exchange was 
conducted by passing FY26.I through Dowex® 1X4 chloride form resin, yielding FY26.Cl. 
 
Synthesis of FY26.Cl 
[Os(η6-p-cym)Cl2]2 (4.0 g, 5.06 mmol) was dissolved in methanol (50 mL) and heated to 80 °C. A 
solution of potassium iodide (84.0 g, 505.91 mmol) in water (50 mL) was added and the mixture 
stirred for 5 min. A solution of N,N-dimethyl-4-(2-pyridylazo)aniline (2.4 g, 10.62 mmol) in methanol 
(50 mL) was added drop-wise and the mixture was stirred for 1 h at 80 °C, and left stirring for 18 h at 
ambient temperature. The majority of methanol was removed under reduced pressure using a 
rotavap and the product was extracted with dichloromethane (100 mL), and washed with water (100 
mL). More product was extracted from the aqueous layer with dichloromethane washings (4 × 50 
mL). The combined dichloromethane extracts were vacuum filtered to remove a black impurity, and 
the filtrate was dried under reduced pressure. The solids were fully redissolved in a mixture of 
ethanol (200 mL) and dichloromethane (50 mL). The volume of the solution was reduced using a 
rotavap to ~40 mL and a precipitate formed, then the mixture was placed in a freezer (-20 °C) 
overnight. The intermediate product (FY26.I) was collected via vacuum filtration and washed with 
ice-cold ethanol (~10 mL), then diethyl ether (6 × 50 mL). The washes were repeated once more. 




































Mobile phase; acetonitrile/water + 0.1% trifluoroacetic acid), and dissolved in methanol (100-150 
mL).  
A chromatography column (250 mL) containing Dowex® 1X4 chloride form resin was prepared 
(Sigma-Aldrich, Dorset, UK). The resin was flushed with aqueous sodium chloride solution (0.1 g/mL, 
0.8 L), water (1.0 L), methanol:water (1:1, v/v, 0.8 L), then methanol (0.4 L). The FY26.I methanol 
solution was passed through the column using methanol as an eluent. The dark-blue complex was 
collected and any other fractions were discarded. The extract was evaporated to dryness under 
reduced pressure, and the solids were redissolved in a minimum volume of dichloromethane. This 
was dried once more under reduced pressure, forming a shiny flaky dark-blue amorphous solid, 
which was isolated and dried overnight in a vacuum desiccator. Yield: (7.09 g, 98%). 1H NMR 
((CD3)CO): δ 9.91-9.93 (m, 1H), 8.56-8.58 (m, 1H), 8.15-8.22 (m, 3H), 7.56-7.60 (m, 1H), 6.93-6.95 (m, 
2H), 6.81-6.82 (m, 1H), 6.68-6.70 (m, 1H), 6.34-6.36 (m, 1H), 6.28-6.29 (m, 1H), 3.35 (s, 6H), 2.77 (s, 
3H), 2.52 (sept., 1H, J = 6.9 Hz), 0.97 (d, 3H, J = 6.9 Hz), 0.91 (d, 3H, J = 6.9 Hz). ESI-MS calculated for 
C23H28IN4Os+: m/z 679.1. Found: 679.1. CHN and Cl analysis: Found: C, 38.99%; H, 4.57%; N, 7.22%.; 
Cl, 4.69%. Calculated for C23H28ClIN4Os: C, 38.74%; H, 3.96%; N, 7.86%; Cl, 4.97%. HPLC purity: 99.1%. 
 
Comparative solubility study 
One to 5 mg of FY26.PF6 or FY26.I, and 180 mg FY26.Cl was dispensed into falcon tubes in triplicates, 
then 1 mL of doubly deionised water was added. The falcon tubes were placed on a Vibrax VXB basic 
shaker (Sigma-Aldrich, Dorset, UK) for 24 h at a speed of 500 g/min (ambient temperature 18-20 °C), 
and were checked at intervals (further solids were added if total saturation appeared to occur). The 
samples were filtered through syringe filters (PTFE, 0.45 µm, 4 mm) to remove any undissolved 
solids. The concentrations of the solutions (Os) were measured using inductively coupled plasma-






































Separation of FY26 enantiomer via chiral HPLC  
A solution of FY26 in EtOH (1 mg/mL) was prepared and filtered through a syringe filter (PTFE, 4 mm 
x 0.45 μm). Preparative chiral HPLC was carried out using an Agilent Technologies 1200 series HPLC 
instrument with a VWD and 1 mL loop. The instrument was fitted with a DAICEL Group (Chiral 
Technologies Europe) Chiralpak IC cellulose-based semi-preparative column (250 x 10 mm, 5 µm 
pore size), and a guard column (Same brand and stationary phase; 10 x 20 mm, 5 µm pore size). The 
mobile phase consisted of EtOH:n-heptane (1:1, v/v), with 0.5% trimethylamine (TEA, v/v) and 0.3% 
triflouroacetic acid (TFA, v/v) additives. The mobile phase was isocratic with a flow rate of 3 mL/min. 
Aliquots of 40× of 500 μL were injected manually with a sample run time of 30 min (wavelength of 
detection = 254 nm). Two distinct peaks were observed at retention times 17.9 min (enantiomer 1) 
and 20.3 min (enantiomer 2), and collected manually. Combined fractions were evaporated to 
dryness, re-dissolved in MeCN:H2O (1:9, v/v, 10 mL), and purified by preparative reverse-phase HPLC 
to remove excess TEA and its salts. Excess NH4PF6 (~100 mol equiv) was combined with each 
enantiomer and the HPLC solvents were removed under reduced pressure. The enantiomers were 
dissolved in DCM (5 mL), filtered, dried under vacuum, and stored in a freezer (-20 °C). 
 
Biological Assays 
A first in vitro study investigated the relevance of iodide or chloride anion for the maximum 
solubility and cytotoxicity of FY26. Five in vivo experiments (Exp 1 to 5) were performed involving a 
total of 170 mice in order to determine (i) the antitumour efficacy of FY26 against measurable 
hepatocarcinoma (Hepa1-6-Per2-luc); (ii) the possible limiting toxicity and the influence of dosing 







































Dulbecco’s Modified Eagle’s Medium (DMEM) cell culture media, penicillin/streptomycin, foetal 
bovine serum, L-gutamine, phosphate buffered saline solution (PBS) and trypsin/EDTA were all 
purchased from Thermo Fisher (Loughborough, UK). DMEM was supplemented with 10% foetal 
bovine serum, 1% penicillin/streptomycin and 2mM L-glutamine . Cancer cell lines (A2780 and A549) 
were purchased from the European Collection of Cell Cultures (Salisbury, UK). Cell cultures were 
grown in T-75 or T-175 culture flasks as adherent monolayers. The cells were passaged 2-3 times per 
week whenever confluence reached 80-90%, using 0.25% trypsin/EDTA. Cell cultures were stored in 
an incubator at 37 °C with a 5% CO2 humidified atmosphere. 
 
In vitro growth inhibition assay 
Five thousand A2780 or A549 cells were seeded per well in 96-well plates. The cells were pre-
incubated in drug-free media at 37 °C for 48 h before adding a range of concentrations (0.01-100 
µM) of the complexes to be tested. Typically, the complex was dissolved in DMSO at 2 mM 
concentration, then diluted with cell culture medium to give a 100 µM stock solution with 5% v/v 
DMSO. Cells were exposed to complexes for 24 h at 37 °C. The supernatants were removed by 
suction and each well was washed with PBS. The cells were allowed to recover for 72 h in a drug-free 
medium at 37 °C. The SRB assay was used to determine cell viability23. Absorbance measurements of 
the solubilised dye (Thermo Scientific Multiskan FC with SkanIt software 4.1 for Windows using a 470 
nm filter) allowed the determination of viable treated cells compared to untreated controls. IC50 
values (the concentration at which 50% cell death occurs) were determined as triplicates of 
duplicates for each complex. ICP-OES was used to determine the osmium concentrations of the 







































Analyses of FY26 solutions were carried out on a Perkin Elmer (Optical Emission Spectrometer) 
Optima 5300 DV instrument. All samples and standards were prepared fresh on the day in doubly 
deionised water with distilled HNO3 (3.2%), thiourea (5 mM), and ascorbic acid (0.1 g/L). The 
osmium standard was diluted to the following concentrations for the calibration curve: 0, 25, 50, 
100, 200, 400, 600, 800 and 1000 ppb. The samples were diluted by serial dilutions of typically 1 in 
10 until their concentrations fitted within the calibration range and % total dissolved solids were 
below 0.2%. Samples were prepared in triplicates and the Os optical emissions at 228.226 and 
225.585 nm were detected and integrated. 
 
Animals  
Male CD1-Foxn1nu or C57Bl/6 (B6) mice aged 5-10 weeks (Janvier, Le Genest St Isle, France) were 
housed in groups of 3-4 mice per cage in temperature-controlled (23 ± 1 °C), ventilated 
(100 ± 10 L/min) and light tight chronobiologic animal facilities (Eurobioconcept, Bonneuil s/Marne, 
France). They were synchronized with an alternation of 12 h of light (L) and 12 h of darkness (D) 
(LD12:12), with light starting at 07:00, and had ad libitum access to food and water throughout all 
the experiments. In line with convention, onset of light and that of darkness are referred to as 
Zeitgeber Time 0 (ZT0) and ZT12, respectively. After one or more weeks on this regimen and on the 
day prior to tumour inoculation, both flanks of each B6 mouse were shaved using clippers. 
 
Tumour inoculation and growth assessment  
Mouse hepatocarcinoma (Hepa1-6, ATCC® CRL-1830™) were kindly provided by S. Dulong (INSERM 
U935, Villejuif, France), following their stable transfection with the Per2-luc (pLV7-Bsd-P(Per2)-dLuc) 
reporter constructs within the C5SYS ERASYSBIO+ project (FP7). Mouse Hepa1-6 Per2-luc cells were 




































the cells were trypsinised and resuspended at a concentration of 106 cells/100 µL in PBS solution 
alone (Exp 1-2) or with 1:1 MatriGel (Corning, Flintshire, UK) (Exp 3-5) and kept on ice until 
injected. 
The mice, aged 8 to 10 weeks, were anesthesized under isoflurane and Hepa 1-6-Per2-luc cells were 
injected subcutaneously in both postero-lateral flanks of each mouse. Mice were then inspected and 
weighed daily until experiment completion. Tumour sites were inspected daily until tumours became 
palpable and amenable to daily measurements of perpendicular diameters using callipers. 
Measurements were always taken at the same circadian time. 
Mean daily tumour weight per mouse was calculated as the average volume of the right and left 
flank tumours according to (L x W2)/2, where L is the larger and W the smaller perpendicular 
diameter, and 1 cm3 corresponds to 1 g. Mice with an estimated tumour weight exceeding 10% of 
their body weight, or those in poor general condition or loosing >15% of their starting body weight 
were euthanized in compliance with our Home Office Project Licence specifications approved by the 
Animals in Science Committee (ASC) and  Animal Welfare and Ethical Review Body (AWERB). 
  
Experiment objectives and design 
All experiments were performed in compliance with the UK relevant laws and institutional 
guidelines, and were approved by the Animals in Science Committee (ASC) and the Animal Welfare 
and Ethical Review Body (AWERB) of the University of Warwick.  
Exp 1 aimed at the determination of a therapeutic dose of the less soluble FY26.PF6 formulation. 
Hepa1-6-bearing nude mice were randomly assigned to be injected intraperitoneally (ip) with vehicle 
(controls), or 40, 60 or 80 mg/kg/inj of FY26.PF6 at ZT6 (in the middle of the light span) every other 
day for 12 days (Table 1).  
Exp 2 aimed at assessing whether FY26.PF6 circadian timing would influence toxicity or efficacy in 




































mg/kg/inj) at ZT6 or at ZT18 (4 controls and 6 treated mice per ZT) every other day for 11 days (6 
injections; cumulative dose, 300 mg/kg).  
Exp 3 aimed at assessing the efficacy and tolerability of the more soluble formulation of FY26.Cl in 
Hepa1-6-bearing C57Bl/6 mice. The mice were randomized to receive vehicle or FY26.Cl, at a 
cumulative dose of 60 mg/kg. Treated mice received ip injections of 20 mg/kg of FY26.Cl at ZT6 12, 
14 and 17 days after tumour inoculation. Control mice received ip vehicle on the same days.  
Exp 4 aimed at confirming efficacy and optimizing timing and scheduling of the same cumulative 
dose of 60 mg/kg of FY26.Cl. Mice were randomized to receive either vehicle or FY26.Cl as 4 
injections of 15 mg/kg at ZT6 or ZT18 on days 11, 14, 17 and 21.  
Exp 5 determined FY26.Cl uptake in mouse tumour and liver. Hepa1-6 bearing mice were randomly 
assigned to either treatment or control groups. They received a single ip injection of 5, 10, or 20 
mg/kg of FY26.Cl or 0.1 M PBS (vehicle) at ZT6 (Table 1). The mice from pre-set subgroups were 
culled at 6, 24 or 48 hours after injection. The subcutaneous tumours in both flanks, as well as liver, 
spleen, one kidney, an ileum and a colon segment and brain were sampled and stored at -80 °C. 
 
FY26 sample preparation 
For Exp 1-2, FY26.PF6 was diluted in the vehicle, composed of 1% TWEEN 80 (Sigma Aldrich, 
Gillingham, UK), 5% DMSO (Corning, New York, USA) and 94% of 0.9% saline (Prep room, Life 
Sciences, University of Warwick) under laminar flow. FY26.PF6 concentration was confirmed with 
ICP-MS. For Exp 3-5, using FY26.Cl, a stock solution of 50 mg/mL FY26.Cl was prepared in 0.9% saline 
on the day of injection and diluted as required; the vehicle consisted of 0.9% saline. 
 
Tissue sample preparation and chemical digestion 
Liver tissue was homogenised by manual mechanical grinding (pestle and mortar) whilst frozen 
under liquid N2. Once thawed, approximately 90-110 mg of homogenised tissue was pipetted into 




































was added. Tumour tissue was not homogenised and instead digested as whole tissues. It was 
weighed directly into microwave vials and TMAH was added (100 µL per 5 mg tissue, minimum of 
500 µL added). The samples were digested via microwave irradiation (CEM SP-D Discover® 
microwave reactor, ≥300 W, ≥450 PSI) at 200 °C for 10 min. Digested samples were diluted in 1 part 
doubly-deionised water (DDIW), then centrifuged at 9000 rpm for 10 min at 20 °C. The final 
analytical samples were prepared by a further 1 in 12.5 dilution in DDIW (total dilution of 1 in 25), 
ensuring that the final concentration of TMAH is 1% and the total dissolved solids were <0.1%. 
TMAH digestion was selected to circumvent the formation of volatile Os species with nitric acid. 
 
ICP-MS analysis 
Analyses of digested tissue samples were carried out on an Agilent Technologies ICP-MS 7900 
spectrometer in a basic aqueous matrix of TMAH (1%, m/v). The osmium concentrations were 
determined via isotopic detection of 189Os in gas (He) and no-gas modes, and samples were 
referenced internally to 100Ru (10 ppb). A concentration calibration curve was produced by serial 
dilutions of an osmium standard (1000 ppm) in 1% TMAH: 0, 0.1, 0.25, 0.5, 1, 2.5, 5, 10, 25, 50, 100, 
250, 500 and 1000 ppb. 
 
Statistical methods 
Body weight data were expressed as % body weight measured on the first treatment day. Tumour 
weights in individually treated mice were expressed as % of the median control values, in order to 
determine % inhibition. Mean and Std error (SE) or median and interquartiles were computed for 
the different treatment groups and experimental conditions, i.e., drug timing and day of assessment. 




































Table 1: Endpoints, and main characteristics of the five mouse experiments (Exp). 




Endpoints Daily FY26 
dose (mg/kg) 
and ZT 
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Comparability of FY26.X maximum solubilities 
The maximum aqueous solubilities of FY26.X (where X = PF6, I, or Cl) were determined in doubly-
deionised water. Their solubilities were measured as 0.0201 (± 0.0007), 1.29 (± 0.01), and 215 (± 10) 
mM for X = PF6, I and Cl, respectively. A dramatic 10,448-fold increase in solubility is observed by 
switching the counter-anion from PF6 to Cl (Figure 2). 
 
In vitro antiproliferative activity of FY26.X and its enantiomers 
The antiproliferative activity of FY26.X was measured in A2780 ovarian cancer cells, where X, the 
counter-anion, was varied (PF6 or Cl, Figure 3). The data confirm the lack of any statistically 
significant difference in anticancer activity between the new highly soluble formulation (X = Cl) and 
the older formulation (X = PF6). Furthermore, FY26 has a chiral metal centre and exists as a racemic 
mixture of two enantiomers as shown by its X-ray crystal structure.24 As previously reported for 
FY26.PF6 18, FY26.Cl similarly did not induce apoptosis on exposure in A2780 cells but did induce an 
increase in reactive oxygen species (data not shown). Herein, the enantiomers were separated via 
chiral HPLC and individually tested against A2780 ovarian and A549 lung cancer cells (Figure 3). The 
activity of both enantiomers was similar for A549 cells, however, that of one enantiomer was twice 
as large as that of the other one for A2780 cells. 
 
Dose and time dependencies of FY26.PF6 effects in tumour-bearing nude mice 
In Exp 1 and 2, tumours grew exponentially up to a median value of circa 1.2 and 1 g respectively, 
which was reached 14 days after inoculation. In Exp 1, a dose-response was documented for tumour 
inhibition, with efficacy ranking as highest for the dose of 80 mg/kg/inj, intermediate for that of 40 




































with the higher dose being clearly too toxic since all the mice treated at this dose level were 
euthanized after up to 5 injections (cumulative dose of 400 mg/kg).21 
In Exp 2, tumour growth slowed down transiently after the 6th FY26.PF6 dose, with a slightly better 
efficacy at ZT6 (Figure 4A). Body-weight loss was less pronounced in the mice treated at ZT6 as 
compared to ZT18 (Figure 4B). 
 
Schedule-dependent anti-tumour efficacy of FY26.Cl in C57Bl/6 mice 
The distributions of mean tumour weights per mouse were similar in control and treatment groups 
both within and between experiments before FY26 treatment in Exp 3 and 4. Indeed, no statistically 
significant difference was found for comparisons of treatment vs control groups (p = 0.843) or for 
that of Exp 3 vs Exp 4 (p = 0.671), and no interaction term was validated, with two-way ANOVA. 
Large interindividual variations were found however, since the average tumour weight that was 
measured in each mouse varied by >10-fold in both control and treated groups of each Exp.  
 
The tumour weights in controls nearly doubled over the 8-12 days following the first vehicle 
administration, but did not exceed 0.25 g, thus indicating a slower tumour growth in the C57B/L6 
mice 
(Exp 3-4) as compared to the CD1-Foxn1nu (Exp 1-2). Spontaneous partial tumour regressions and 
regrowth were noticed. Tumours tended to be smaller in the treated mice throughout each Exp, and 
a clear antitumour effect of FY26.Cl was demonstrated 20 and 23 days after tumour inoculation in 
Exps 3 and 4, respectively (Figure 5). The treated mice in both experiments had then received a 
cumulative dose of 60 mg/kg over 5 days for Exp 3, and over 10 days for Exp 4. For Exp 3, the median 
tumour weight was 30.2 mg for the treatment group and 128.8 mg for the control group on day 20 
(Figure 5A).  In Exp 4, these respective values were 122.3 mg (treatment groups ZT6 & ZT18) and 
213.2 mg (control group) on day 23 (Figure 5B). The higher dose intensity of FY26 was associated 




































completion, the median percentage of FY26.Cl-induced tumour inhibition relative to controls was 
76.5% in Exp 3, where the drug was given at ZT6 only, and 42.6% in Exp 4 irrespective of dosing time. 
At the end of Exp 4, the percentage inhibition relative to control was 12.5% in the mice dosed with 
FY26.Cl at ZT6 and 66% in those treated at ZT18 (Kruskall Wallis ANOVA, p=0.022) (Figure 5D). FY26 
efficacy, however, could be determined only for those mice that survived the treatment toxicities.  
 
Circadian timing-dependent toxicity of FY26.Cl 
Thus, at study completion, 13/20 controls in Exp 3, and 10/10 controls in Exp 4 were alive, 
representing an overall rate of 23/30 controls for both Exp (76.7%). Seven control mice (23.3%) had 
to be euthanised due to tumour progression. In contrast, severe clinical toxicity signs were observed 
that mandated euthanizing nearly half of the treated mice for ethical reasons. As a result, 8/16 
(50%) and 9/20 treated mice (45%) were alive at completion of Exp 3 and 4, respectively. In Exp 4, 
overall survival was best following FY26 dosing at ZT6 as compared to ZT18 with respective survival 
rates of 60% vs 30% (Gehan-Breslow-Wilcoxon test, p=0.0012). Body weight loss, however, did not 
correlate with other signs of physical condition that triggered humane endpoints. 
 
Daily body weights increased gradually in controls over the respective treatment durations in each 
experiment. The FY26-treated mice displayed a modest yet consistent decrease in body weight as 
compared to pre-treatment values in both experiments. Body weight was primarily reduced after 
the second injection then remained rather stable despite further FY26 administrations (Figure 6)  
 
Thus, the body weight changes showed a significant difference between the treated and the control 
group after the third dose in each Exp. After a cumulative dose of 60 mg/kg of FY26.Cl, mice lost 
~10% (± 3.2%) of their body weight before treatment. Body weight loss from FY26 dosing was clearly 
worse at ZT18 as compared to ZT6 (Figure 6B). Mann Whitney test validated significant differences 




































of drug timing (p= 0.0017 and p= 0.0059, for Exp1 and 2 respectively), as well as for circadian timing 
effects (Dunnett's multiple comparisons test, p<0.0001).  
 
FY26 tumour and liver pharmacokinetics and pharmacodynamic correlations 
Following the administration of FY26.Cl to Hepa1-6 Per2-luc tumour-bearing mice at ZT6, the tissue 
[Os] concentrations varied as a function of dose at 6 h, in the tumours in each flank and in liver 
(Figure 7). Based on these data, FY26.Cl tumour  uptake was nearly ten-fold less in both tumours as 
compared to liver at 6 h post treatment. 
 
The tumour [Os] levels remained almost constant over time in the mice dosed with 20 mg/kg, with 
similar values in the right and left flank tumours sampled at 6, 24 and 48 h after injection (Figure 7A-
B). In contrast the [Os] in the tumours of both flanks decreased at 24 h and slightly increased at 48 h 
for both lower dose levels (10 and 5 mg/kg). In the liver, similar [Os] concentrations were found 6 h 
after dosing the mice with 20 or 10 mg/kg, while [Os] levels nearly halved in the mice treated with 5 
mg/kg (Figure 7C). Liver [Os] levels remained almost constant until 48 h for the mice treated with 20 
mg/kg of FY 26.Cl. In contrast, the liver [Os] concentrations decreased sharply at 24 h and remained 
stable until 48 h for the 10 and 5 mg/kg doses. 
 
Taken together, these tissue pharmacokinetics data suggest that some uptake saturation 
mechanisms and efflux blockage for at least 48 h are reached both in the tumour and in the liver 
with a single ip dose of 20 mg/kg of FY26.Cl. The partial clearance of liver Os at 24 h in the mice 
dosed with 10 or 5 mg/kg could result in Os re-uptake by the tumours from the bloodstream, hence 
accounting for the slight tumour [Os] increase at 48 h, and might possess a better therapeutic index.  
 
All the treated mice lost some weight 24 and or 48 h post dosing, while controls gained some weight 




































level and day of assessment. The limited sample size and low toxicity of a single dose precluded the 
demonstration of any dose-response relationship, using body weight changes as an endpoint. No 
changes in tumour volumes were found, as expected following a single FY26 dose. 
 
DISCUSSION 
Currently, the most widely administered drugs in cancer chemotherapy are platinum complexes 
(cisplatin, carboplatin and oxaliplatin).25 Despite the clinical efficacy of these drugs, there is a need 
for new drugs with different mechanisms of action which can circumvent platinum resistance, widen 
the spectrum of activity, and reduce side effects.26  
 
Organo-osmium anticancer complexes with PF6 anions have high crystal packing energies, and we 
previously reported that solubility can be improved up to 45-fold by switching to CF3SO3 anions.22 
Here we show that FY26.X solubility is vastly improved 10,448-fold by switching to a chloride anion. 
Such drastic solubility improvements eliminate the need for DMSO in biological assays and improve 
viability for clinical use. Furthermore, since the active component is the organo-osmium cation, the 
change in anion did not significantly alter its pharmacological activity. 
 
Amongst other precious metals, complexes of Os(II), also a 3rd row transition metal, and 
isoelectronic with Pt(IV), show promise. Here we have studied the organo-osmium(II) half-sandwich 
complex FY26 ([OsII(ɳ6-p-cym)(PhAzPy-NMe2)I]+, a pseudo-octahedral complex in which the arene, p-
cymene occupies 3 coordination positions, the phenylazopyridine ligand is chelated, and a strongly 
bound iodide ligand completes the coordination sphere.27 
FY26 is a relatively inert complex that does not readily hydrolyse even after 24 h incubation at 37o C 
in aqueous solution at pH 7.4, or react with DNA bases.12 However, radiolabelling studies with 131I 
have shown that the complex is activated in cancer cells and the iodide ligand is rapidly excreted.16.= 




































abundant intracellular tripeptide glutathione, which weakens the Os-I bond.17 This complex appears 
to act as a metabolic inhibitor, inducing cell apoptotic death via ROS generation.3, 4 The mechanism 
also involves the arrest of cycling cells in G1-phase, thus halting cellular proliferation.12 
 
Here, a consistent yet moderate efficacy of the osmium complex FY26 was demonstrated in 
hepatocarcinoma-bearing mice, as indicated with a circa 60% tumour inhibition as compared to 
controls using the more soluble FY26.Cl. Indeed, both FY26.Cl and the FY26.PF6 displayed some 
efficacy in this tumour model, both in vitro and in vivo.21  Reaching a cumulative dose of 60 mg/kg 
appeared to be necessary for FY26.Cl efficacy to become apparent. 
 
Since the circadian clock regulates both cellular metabolism and the cell cycle,6, 7 we sought whether 
circadian timing would moderate FY26 effects in this mouse hepatocarcinoma model, both in cell 
cultures and in tumour-bearing mice, and aimed at the determination of implications for 
optimization of treatment schedules.  
 
The dosing time of FY26 significantly impacted on FY26 tolerability, as indicated by the loss in body 
weight of the tumour bearing mice. The mice treated at ZT18 showed larger loss in body weight as 
compared to those treated at ZT6. This was consistent both in the current studies using FY26.PF6 or 
FY26.Cl, and in prior experiments where FY26.PF6 had been administered at six ZT’s in non tumour-
bearing mice.21 
 
The blockbuster platinum complex oxaliplatin has largely benefitted from circadian research early 
on, at a time when its development as an anticancer drug had been halted for undue clinical 
toxicities.28 More specifically, the toxicities of oxaliplatin, like those of carboplatin and cisplatin, 
were halved or reduced even more through their administration in mice or rats during their 




































were enhanced following dosing at the time when both drugs were least toxic. 31, 32 Moreover, early 
afternoon delivery of oxaliplatin significantly improved tolerability and efficacy of oxaliplatin in 
metastatic colorectal cancer patients. 9, 33 Reduced glutathione plays a key role in the circadian 
detoxification mechanisms of the platinum complexes. Thus the  cytosolic concentrations of reduced 
glutathione more than doubled along the 24-hour time scale in mouse liver with a statistically 
significant circadian rhythm.34 The 24-hour mean of GSH concentrations was more than halved 
following the administration of L-buthionine sulfoximine (L-BSO), an inhibitor of gamma-
glutamylcysteine synthetase, a rate limiting enzyme of GSH synthesis. Moreover the GSH pattern 
became bimodal over the 24 hours after L-BSO exposure. The rhythmic patterns in cisplatin toxicities 
closely matched those in GSH. Thus the prominent circadian rhythm that characterized cisplatin29, 30 
was drastically altered in the BSO-treated mice,  with a  5.7 fold reduction in average survival rate , 
and a shift in the period of cisplatin toxicity rhythm from 24-h to 12-h.35 Reduced glutathione, 
however, appeared to have a dual role for FY26 pharmacology, i.e. it can facilitate the bioactivation 
of FY26 into the corresponding aqua-species, but also detoxify cells from the chloride adduct FY26. 
This may account for the several hours’ difference regarding the circadian times of administration 
that optimize the tolerability of platinum complexes on the one hand, and of FY26 on the other 
hand, both in vitro and in vivo.21 29, 30 
 
In spite of the larger body weight loss, the mice receiving FY26.Cl at ZT18 had a larger tumour weight 
reduction as compared to those injected at ZT6. The apparent increase in antitumour efficacy 
following dosing at the circadian time of poor tolerability strikingly differs from prior findings with 
other anticancer agents including cisplatin and oxaliplatin. Thus, the dosing time of best efficacy 
coincided with that of best tolerability for 28 anticancer drugs.6-8 However, spontaneous regressions 
and regrowth characterized the experimental model we used here, thus indicating the occurrence of 
host immunologic responses against the subcutaneous Hepa 1-6 tumours, which were growing in 




































treatment schedules should indeed aim to reduce the exposure of healthy tissues to FY26.Cl through 
drug dosing at ZT6, because (i) a significant tumour drug uptake was demonstrated at this time, (ii) a 
significant tumour inhibition was achieved in mice treated at this time with the more dose intensive 
schedule (Exp 3), and (iii) the optimization of drug tolerability was crucial for outcomes (Exp 4). 
 
Conclusions 
Here, we have demonstrated that FY26.Cl and FY26.PF6 are least toxic to the mice, following dosing 
near the middle of their resting span, during daytime. The circadian pattern in the FY26.Cl 
tolerability that was found here, was similar to that demonstrated earlier for the less soluble 
FY26.PF6 formulation. The circadian optimization of tolerability appeared potentially useful, because 
FY26-induced antitumour efficacy required treatment with repeated administrations. Thus good 
tolerability would favor compliance to the subchronic treatment that was needed to achieve 
efficacy. Since the tumour drug levels remained similar at 48 h-post dose, irrespective of dose level, 
we propose to enhance treatment efficacy through the daily delivery of low dose levels (i.e., 5-10 
mg/kg) at ZT6, a high dose intensity schedule which could be automatically delivered using 
“intelligent” nanoparticles.  
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Figure 1. Schemes of FY26 molecular structures and action mechanisms. (A) Structure of the 
organo-osmium azopyridine complex FY26 and abbreviations used for the PF6- and Cl- salts. (B) 
Proposed biomolecular mechanisms for the cytotoxicity of FY26 involving intracellular activation by 








































Figure 2. Bar graph of the dependence of the  maximum solubilities of FY26.X on the the anion X,in 
water (where X = PF6-, I- or Cl-). Data are mean ±SD of N=3, being 0.0201 (± 0.0007), 1.29 (± 0.1), and 

















































































Figure 3. Bar-graphs illustrating the in vitro anticancer efficacy of different forms of FY26. (A) 
Antiproliferative activities of FY26.PF6 and FY26.Cl against A2780 cancer cells. Data represent Mean 
±SD of N=6. (B) Antiproliferative activities of the FY26 enantiomers against A2780 and A549 cancer 























FY . FY . l A549 cells A2780 cells
FY26 Enantiomer 1





































Figure 4: Dosing time effects of FY26 in Hepa1-6-bearing nude mice (Exp 2). Effects of FY26.PF6 (50 
mg/kg/inj) on tumour weights (A), and body weight changes (B), according to injection timing 






































Figure 5: Antitumour efficacy of FY26.Cl in Hepa1-6-bearing C57Bl/6 mice. Growth curves of 
inoculated Hepa1-6 Per2-luc tumours in male C57Bl/6 mice treated with vehicle (control groups) or 
FY26.Cl (treated groups). Median daily tumour volumes (± interquartiles) in treated mice or controls 
receiving vehicle. (A) Exp 3, with mice in treated group with 20 mg/kg of FY26.Cl i.p per injection x 3 
injections. (B) Exp 4, with mice in treated group dosed with 15 mg/kg of FY26.Cl ip per injection x 4 
injections. (C) FY26.Cl induced tumour weight (%) inhibition relative to median control tumour 
weight. (D)  Tumour weight inhibition (%) relative to median control tumour weight, according to 






































Figure 6: Relative changes in body weight following vehicle (control groups) or FY26.Cl (treated 
groups) administration in Hepa1-6 Per2-luc tumour-bearing mice treated in two experiments. 
Median daily body weight (± interquartiles). (A) Exp 3, mice in treated group receiving 20 mg/kg of 
FY26 i.p per injection ×3 injections at ZT6. (B) Exp 4, mice in treated group dosed with 15 mg/kg of 
FY26 ip per injection ×4 injections at ZT6 or ZT18.  
  





























































































































Figure 7: Dose-dependent kinetics of osmium concentrations in tumour and liver tissues from mice 
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